Hutchmed (China) Limited American Depositary Shares (HCM)
HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript
HUTCHMED (China) Limited ( HCM ) HUTCHMED (China) Limited Deutsche Bank ADR Virtual Investor Conference 2025 November 4, 2025 8:00 AM EST Company Participants David Ng - Head of Investor Relations & Capital Strategies Conference Call Participants Zafar Aziz - Deutsche Bank Aktiengesellschaft Presentation Zafar Aziz Deutsche Bank Aktiengesellschaft Hello, and Welcome to Deutsche Bank's Virtual Investor Conference, dbVIC. This is Zafar Aziz from the Deutsche Bank team.
HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript
HUTCHMED (China) Limited ( HCM ) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update October 31, 2025 8:00 AM EDT Company Participants David Ng - Head of Investor Relations & Capital Strategies Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Conference Call Participants Alec Stranahan - BofA Securities, Research Division Khalil Fenina - Goldman Sachs Group, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Adam McCarter - Cavendish Securities plc, Research Division Presentation David Ng Head of Investor Relations & Capital Strategies Hello, everyone. Good evening and good morning.
HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Chig Fung Cheng - CFO & Executive Director David Ng - Head of Investor Relations & Capital Strategies George Yuan - Corporate Participant Ming Shi - Executive VP, Head of R&D and Chief Medical Officer Wei-Guo Su - CEO, Chief Scientific Officer & Executive Director Conference Call Participants Chen Chen - UBS Investment Bank, Research Division Matthew Yan - Unidentified Company Paul Choi - Goldman Sachs Group, Inc., Research Division David Ng Hello, everyone. This is David Ng, Head of Investor Relations of HUTCHMED.
How Much Upside is Left in HUTCHMED (HCM)? Wall Street Analysts Think 73.52%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.5% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Paycom Software: Automating Payroll And HCM Solutions; Initiate With 'Buy'
I am initiating Paycom with a 'buy' rating and a $280 fair value, driven by strong automation-focused HCM solutions. Paycom's innovations like Beti and GONE automate payroll and time-off processes, supporting double-digit topline growth and high customer ROI. The company is expanding into mid-to-large enterprise markets, leveraging AI and automation to capture market share and drive 9% organic revenue growth.
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HUTCHMED shares rise 10% as Phase II gastric cancer trial hits key milestone
Shares in Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013) rose 10% in early trading on Tuesday after the biopharma company announced it had completed patient enrolment for a key phase II trial of its cancer drug savolitinib in China. The study is testing the treatment in people with gastric or gastroesophageal junction cancer whose tumours show MET gene amplification - a relatively rare but aggressive subtype.
3 Internet Delivery Services Stocks in Focus Amid Industry Challenges
Tariff war, inflationary pressure and still-high interest rates are major concerns for the Zacks Internet - Delivery Services industry. However, efforts to adopt consumer preferences and technological advancements are likely to help GDDY, QNST and ASUR navigate the headwinds.
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM).
US pharma restrictions won't affect Hutchmed operations, says CEO
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external challenges.
HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM ) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO George Yuan - Head of Commercial Michael Shi - EVP, Head of R&D & Chief Medical Officer Conference Call Participants Clara Dong - Jefferies Alec Stranahan - Bank of America Julie Simmonds - Panmure Liberum Adam McCarter - Cavendish Chen Chen - UBS Cindy Chai - HSBC David Ng Welcome, everyone. Thank you for joining HUTCHMED 2024 Full Year Results Call.
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 million.
